KENTUCKY BOARD OF PHARMACY State Office Building Annex, Suite 300 125 Holmes Street Frankfort KY 40601

Special Meeting Notice and Agenda

Hazardous Compounding Committee

April 9, 2018 9:00 a.m.

- I. Call to Order
- II. Minutes March 12, 2018
- III. Section 1 Wholesaler Distributors
- IV. Manufactured Products
- V. Next meeting May 14, 2018 Manufactured Products
- VI. Adjournment

Kentucky Board of Pharmacy

Hazardous Drug Compounding Committee

125 Holmes Street Frankfort KY 40601

April 9, 2018

MINUTES

Chair Matt Martin called the meeting to order at 9:08 a.m. Members present: Barb Jolly, Chris Harlow, Trenika Mitchell and Jennifer Grove. Members absent: Alyson Roby, John Carver and Paul Daniels. Staff: Larry Hadley, Katie Busroe, Amanda Harding, John Romines, Cheryl Lalonde and Darla Sayre. Guests: Jason Lyddane, St Joseph Hospital; Don Kupper, New Vitalis Pharmacy; Robin Walters, Pikeville Medical Center; Brittany Reid, Wal-mart; Amanda McCoy, St. Elizabeth; Mark Glaspar, KPHA and Philip Schwieterman, KSHP.

On motion by Dr. Harlow, seconded by Dr. Jolly, the minutes of the February 12, 2018 meeting were approved with one correction. Dr. Martin clarified the wording proposed from the Texas Board of Pharmacy in Section 2 was not approved by the Texas Board of Pharmacy.

Section 1 Wholesale Distributors: Dr. Martin requested tabling this discussion until the June meeting to allow for input from license wholesale distributors. Dr. Mitchell made a motion to table this discussion until the June meeting. Dr. Harlow seconded, and the motion passed unanimously.

Manufactured Products –After much discussion, it was determined that the shipping container for manufactured products was the containment bag within the tote not the tote itself. All parties agreed that pharmacies should have no issues in providing a designated neutral air area for the opening of the containment bag.

Dr. Martin gave a summary of the proposed regulation the committee has decided upon thus far.

Section 1 – no changes Section 2 – no changes other than Box 1 to allow for risk assessment for Table 2 and 3 drugs. Section 3 – no changes Section 4 – no changes Section 8 – no changes Section 9 – no changes Manufactured Products – no changes

Dr. Mitchell made a motion for the following agenda items for upcoming meetings.

May 14, 2018 Sections 5 and 15 June 11, 2018 Wholesale Distributors, Sections 6, 7 and 10

Dr. Harlow seconded, and the motion passed unanimously. Dr. Martin volunteered to write a letter to the wholesale distributor association inviting them to the June meeting.

On motion by Dr. Mitchell, seconded by Dr. Jolly and passed unanimously, Dr. Martin adjourned at 10:12 a.m.